VIEW MORENext-generation SERD imlunestrant significantly improves progression-free survival in patients with ER+/HER2- advanced breast cancer compared to standard therapy
VIEW MOREPatritumab deruxtecan reduces serious side effects in breast cancer patients compared to conventional chemotherapy while maintaining treatment efficacy
Latest News
18 December 2024
Blocking the GDF-15 protein may rescue resistance to immunotherapy against solid tumours
The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra...
11 December 2024
Next-generation SERD imlunestrant significantly improves progression-free survival in patients with ER+/HER2- advanced breast cancer compared to standard therapy
The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination...
11 December 2024
Patritumab deruxtecan reduces serious side effects in breast cancer patients compared to conventional chemotherapy while maintaining treatment efficacy
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard...
09 December 2024
VHIO participates in the European COMBAT-PDAC project to improve the diagnosis and treatment of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other...
PRINCIPAL RESEARCHERS
Events
